nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—CYP2C9—brain cancer	0.501	1	CbGaD
Rabeprazole—CYP2D6—Lomustine—brain cancer	0.0559	0.163	CbGbCtD
Rabeprazole—CYP1A2—Carmustine—brain cancer	0.0553	0.161	CbGbCtD
Rabeprazole—ABCG2—Carboplatin—brain cancer	0.0473	0.138	CbGbCtD
Rabeprazole—CYP2D6—Hydroxyurea—brain cancer	0.0423	0.124	CbGbCtD
Rabeprazole—CYP3A4—Temozolomide—brain cancer	0.0418	0.122	CbGbCtD
Rabeprazole—ABCG2—Etoposide—brain cancer	0.0397	0.116	CbGbCtD
Rabeprazole—CYP3A4—Lomustine—brain cancer	0.0355	0.104	CbGbCtD
Rabeprazole—CYP1A2—Etoposide—brain cancer	0.0164	0.0478	CbGbCtD
Rabeprazole—CYP3A4—Etoposide—brain cancer	0.00858	0.025	CbGbCtD
Rabeprazole—Pantoprazole—CYP2C9—brain cancer	0.00153	0.39	CrCbGaD
Rabeprazole—Omeprazole—CYP2C9—brain cancer	0.00125	0.318	CrCbGaD
Rabeprazole—Lansoprazole—CYP2C9—brain cancer	0.00114	0.291	CrCbGaD
Rabeprazole—CYP1A1—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00107	0.057	CbGpPWpGaD
Rabeprazole—CYP1A1—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00097	0.0519	CbGpPWpGaD
Rabeprazole—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.000872	0.0466	CbGpPWpGaD
Rabeprazole—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.000794	0.0424	CbGpPWpGaD
Rabeprazole—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00068	0.0363	CbGpPWpGaD
Rabeprazole—CYP2C19—CYP2E1 reactions—CYP2C9—brain cancer	0.000676	0.0362	CbGpPWpGaD
Rabeprazole—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.000622	0.0333	CbGpPWpGaD
Rabeprazole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.000619	0.0331	CbGpPWpGaD
Rabeprazole—CYP1A1—Xenobiotics—CYP2C9—brain cancer	0.000512	0.0274	CbGpPWpGaD
Rabeprazole—CYP1A1—Tamoxifen metabolism—CYP2C9—brain cancer	0.000493	0.0263	CbGpPWpGaD
Rabeprazole—CYP2C19—Xenobiotics—CYP2C9—brain cancer	0.000419	0.0224	CbGpPWpGaD
Rabeprazole—CYP2C19—Tamoxifen metabolism—CYP2C9—brain cancer	0.000403	0.0216	CbGpPWpGaD
Rabeprazole—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.000385	0.0206	CbGpPWpGaD
Rabeprazole—ATP4B—Ion channel transport—TRPC6—brain cancer	0.00038	0.0203	CbGpPWpGaD
Rabeprazole—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.000371	0.0198	CbGpPWpGaD
Rabeprazole—ATP4A—Ion channel transport—TRPC6—brain cancer	0.000339	0.0181	CbGpPWpGaD
Rabeprazole—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.000327	0.0175	CbGpPWpGaD
Rabeprazole—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000314	0.0168	CbGpPWpGaD
Rabeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000288	0.0154	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—S100A10—brain cancer	0.000287	0.0153	CbGpPWpGaD
Rabeprazole—ABCG2—Irinotecan Pathway—APC—brain cancer	0.000267	0.0143	CbGpPWpGaD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—S100A10—brain cancer	0.000255	0.0137	CbGpPWpGaD
Rabeprazole—Oedema—Procarbazine—brain cancer	0.000255	0.00191	CcSEcCtD
Rabeprazole—Dysuria—Temozolomide—brain cancer	0.000254	0.00189	CcSEcCtD
Rabeprazole—Neutropenia—Temozolomide—brain cancer	0.000254	0.00189	CcSEcCtD
Rabeprazole—Hyperglycaemia—Carmustine—brain cancer	0.000253	0.00189	CcSEcCtD
Rabeprazole—Angiopathy—Hydroxyurea—brain cancer	0.000252	0.00188	CcSEcCtD
Rabeprazole—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000252	0.0135	CbGpPWpGaD
Rabeprazole—Pneumonia—Carmustine—brain cancer	0.000252	0.00188	CcSEcCtD
Rabeprazole—Shock—Procarbazine—brain cancer	0.000251	0.00187	CcSEcCtD
Rabeprazole—Pollakiuria—Temozolomide—brain cancer	0.000251	0.00187	CcSEcCtD
Rabeprazole—Erectile dysfunction—Temozolomide—brain cancer	0.00025	0.00187	CcSEcCtD
Rabeprazole—Thrombocytopenia—Procarbazine—brain cancer	0.00025	0.00187	CcSEcCtD
Rabeprazole—Chills—Hydroxyurea—brain cancer	0.000249	0.00186	CcSEcCtD
Rabeprazole—Tachycardia—Procarbazine—brain cancer	0.000249	0.00186	CcSEcCtD
Rabeprazole—Photosensitivity reaction—Temozolomide—brain cancer	0.000248	0.00185	CcSEcCtD
Rabeprazole—Weight increased—Temozolomide—brain cancer	0.000247	0.00184	CcSEcCtD
Rabeprazole—Hyperhidrosis—Procarbazine—brain cancer	0.000247	0.00184	CcSEcCtD
Rabeprazole—CYP1A1—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000246	0.0132	CbGpPWpGaD
Rabeprazole—Alopecia—Hydroxyurea—brain cancer	0.000246	0.00183	CcSEcCtD
Rabeprazole—Weight decreased—Temozolomide—brain cancer	0.000246	0.00183	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Carmustine—brain cancer	0.000245	0.00183	CcSEcCtD
Rabeprazole—Hyperglycaemia—Temozolomide—brain cancer	0.000245	0.00183	CcSEcCtD
Rabeprazole—Stomatitis—Carmustine—brain cancer	0.000244	0.00182	CcSEcCtD
Rabeprazole—Urinary tract infection—Carmustine—brain cancer	0.000243	0.00182	CcSEcCtD
Rabeprazole—Pneumonia—Temozolomide—brain cancer	0.000243	0.00182	CcSEcCtD
Rabeprazole—Anorexia—Procarbazine—brain cancer	0.000243	0.00182	CcSEcCtD
Rabeprazole—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000242	0.013	CbGpPWpGaD
Rabeprazole—Erythema—Hydroxyurea—brain cancer	0.000242	0.00181	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.00024	0.00179	CcSEcCtD
Rabeprazole—Nausea—Lomustine—brain cancer	0.000239	0.00178	CcSEcCtD
Rabeprazole—Hypotension—Procarbazine—brain cancer	0.000239	0.00178	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Temozolomide—brain cancer	0.000237	0.00177	CcSEcCtD
Rabeprazole—Stomatitis—Temozolomide—brain cancer	0.000236	0.00176	CcSEcCtD
Rabeprazole—Urinary tract infection—Temozolomide—brain cancer	0.000235	0.00176	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000233	0.00174	CcSEcCtD
Rabeprazole—Insomnia—Procarbazine—brain cancer	0.000231	0.00172	CcSEcCtD
Rabeprazole—Paraesthesia—Procarbazine—brain cancer	0.000229	0.00171	CcSEcCtD
Rabeprazole—Sinusitis—Temozolomide—brain cancer	0.000227	0.00169	CcSEcCtD
Rabeprazole—Somnolence—Procarbazine—brain cancer	0.000227	0.00169	CcSEcCtD
Rabeprazole—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000226	0.00169	CcSEcCtD
Rabeprazole—Ill-defined disorder—Hydroxyurea—brain cancer	0.000225	0.00168	CcSEcCtD
Rabeprazole—Anaemia—Hydroxyurea—brain cancer	0.000224	0.00167	CcSEcCtD
Rabeprazole—Decreased appetite—Procarbazine—brain cancer	0.000222	0.00166	CcSEcCtD
Rabeprazole—Alanine aminotransferase increased—Etoposide—brain cancer	0.000222	0.00165	CcSEcCtD
Rabeprazole—Oedema peripheral—Carmustine—brain cancer	0.000221	0.00165	CcSEcCtD
Rabeprazole—Malaise—Hydroxyurea—brain cancer	0.000218	0.00163	CcSEcCtD
Rabeprazole—Pain—Procarbazine—brain cancer	0.000218	0.00163	CcSEcCtD
Rabeprazole—Constipation—Procarbazine—brain cancer	0.000218	0.00163	CcSEcCtD
Rabeprazole—Hepatitis—Temozolomide—brain cancer	0.000217	0.00162	CcSEcCtD
Rabeprazole—Dysphagia—Etoposide—brain cancer	0.000217	0.00162	CcSEcCtD
Rabeprazole—Leukopenia—Hydroxyurea—brain cancer	0.000217	0.00162	CcSEcCtD
Rabeprazole—Visual impairment—Carmustine—brain cancer	0.000217	0.00162	CcSEcCtD
Rabeprazole—Pharyngitis—Temozolomide—brain cancer	0.000216	0.00161	CcSEcCtD
Rabeprazole—Urinary tract disorder—Temozolomide—brain cancer	0.000215	0.0016	CcSEcCtD
Rabeprazole—Oedema peripheral—Temozolomide—brain cancer	0.000214	0.0016	CcSEcCtD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000214	0.0114	CbGpPWpGaD
Rabeprazole—Urethral disorder—Temozolomide—brain cancer	0.000213	0.00159	CcSEcCtD
Rabeprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000213	0.0114	CbGpPWpGaD
Rabeprazole—Feeling abnormal—Procarbazine—brain cancer	0.00021	0.00157	CcSEcCtD
Rabeprazole—Eye disorder—Carmustine—brain cancer	0.00021	0.00157	CcSEcCtD
Rabeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00021	0.0112	CbGpPWpGaD
Rabeprazole—Convulsion—Hydroxyurea—brain cancer	0.00021	0.00157	CcSEcCtD
Rabeprazole—Visual impairment—Temozolomide—brain cancer	0.000209	0.00156	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Procarbazine—brain cancer	0.000209	0.00156	CcSEcCtD
Rabeprazole—Pancytopenia—Etoposide—brain cancer	0.000206	0.00154	CcSEcCtD
Rabeprazole—Erythema multiforme—Temozolomide—brain cancer	0.000205	0.00153	CcSEcCtD
Rabeprazole—Discomfort—Hydroxyurea—brain cancer	0.000204	0.00152	CcSEcCtD
Rabeprazole—Neutropenia—Etoposide—brain cancer	0.000203	0.00152	CcSEcCtD
Rabeprazole—Eye disorder—Temozolomide—brain cancer	0.000203	0.00152	CcSEcCtD
Rabeprazole—Urticaria—Procarbazine—brain cancer	0.000203	0.00151	CcSEcCtD
Rabeprazole—Tinnitus—Temozolomide—brain cancer	0.000203	0.00151	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000202	0.0108	CbGpPWpGaD
Rabeprazole—Abdominal pain—Procarbazine—brain cancer	0.000202	0.00151	CcSEcCtD
Rabeprazole—Body temperature increased—Procarbazine—brain cancer	0.000202	0.00151	CcSEcCtD
Rabeprazole—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000201	0.0108	CbGpPWpGaD
Rabeprazole—Arrhythmia—Carmustine—brain cancer	0.000201	0.0015	CcSEcCtD
Rabeprazole—Alopecia—Carmustine—brain cancer	0.000199	0.00148	CcSEcCtD
Rabeprazole—Oedema—Hydroxyurea—brain cancer	0.000198	0.00147	CcSEcCtD
Rabeprazole—Angiopathy—Temozolomide—brain cancer	0.000197	0.00147	CcSEcCtD
Rabeprazole—Malnutrition—Carmustine—brain cancer	0.000196	0.00146	CcSEcCtD
Rabeprazole—Erythema—Carmustine—brain cancer	0.000196	0.00146	CcSEcCtD
Rabeprazole—Chills—Temozolomide—brain cancer	0.000195	0.00145	CcSEcCtD
Rabeprazole—Pneumonia—Etoposide—brain cancer	0.000195	0.00145	CcSEcCtD
Rabeprazole—Thrombocytopenia—Hydroxyurea—brain cancer	0.000193	0.00144	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000192	0.00143	CcSEcCtD
Rabeprazole—Alopecia—Temozolomide—brain cancer	0.000192	0.00143	CcSEcCtD
Rabeprazole—Acute coronary syndrome—Etoposide—brain cancer	0.000191	0.00142	CcSEcCtD
Rabeprazole—Myocardial infarction—Etoposide—brain cancer	0.00019	0.00142	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Etoposide—brain cancer	0.00019	0.00142	CcSEcCtD
Rabeprazole—Back pain—Carmustine—brain cancer	0.000189	0.00141	CcSEcCtD
Rabeprazole—Erythema—Temozolomide—brain cancer	0.000189	0.00141	CcSEcCtD
Rabeprazole—Malnutrition—Temozolomide—brain cancer	0.000189	0.00141	CcSEcCtD
Rabeprazole—Jaundice—Etoposide—brain cancer	0.000189	0.00141	CcSEcCtD
Rabeprazole—Stomatitis—Etoposide—brain cancer	0.000189	0.00141	CcSEcCtD
Rabeprazole—Anorexia—Hydroxyurea—brain cancer	0.000188	0.00141	CcSEcCtD
Rabeprazole—Hypersensitivity—Procarbazine—brain cancer	0.000188	0.0014	CcSEcCtD
Rabeprazole—Dysgeusia—Temozolomide—brain cancer	0.000185	0.00138	CcSEcCtD
Rabeprazole—Vision blurred—Carmustine—brain cancer	0.000184	0.00138	CcSEcCtD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—SIRT1—brain cancer	0.000184	0.00986	CbGpPWpGaD
Rabeprazole—Tremor—Carmustine—brain cancer	0.000183	0.00137	CcSEcCtD
Rabeprazole—Asthenia—Procarbazine—brain cancer	0.000183	0.00137	CcSEcCtD
Rabeprazole—Back pain—Temozolomide—brain cancer	0.000183	0.00137	CcSEcCtD
Rabeprazole—Anaemia—Carmustine—brain cancer	0.000181	0.00135	CcSEcCtD
Rabeprazole—Agranulocytosis—Etoposide—brain cancer	0.000181	0.00135	CcSEcCtD
Rabeprazole—Pruritus—Procarbazine—brain cancer	0.000181	0.00135	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.00018	0.00965	CbGpPWpGaD
Rabeprazole—Agitation—Carmustine—brain cancer	0.00018	0.00134	CcSEcCtD
Rabeprazole—Vision blurred—Temozolomide—brain cancer	0.000178	0.00133	CcSEcCtD
Rabeprazole—Tremor—Temozolomide—brain cancer	0.000177	0.00132	CcSEcCtD
Rabeprazole—Dyspnoea—Hydroxyurea—brain cancer	0.000176	0.00131	CcSEcCtD
Rabeprazole—Somnolence—Hydroxyurea—brain cancer	0.000176	0.00131	CcSEcCtD
Rabeprazole—Ill-defined disorder—Temozolomide—brain cancer	0.000175	0.00131	CcSEcCtD
Rabeprazole—Leukopenia—Carmustine—brain cancer	0.000175	0.00131	CcSEcCtD
Rabeprazole—Anaemia—Temozolomide—brain cancer	0.000175	0.0013	CcSEcCtD
Rabeprazole—Diarrhoea—Procarbazine—brain cancer	0.000175	0.0013	CcSEcCtD
Rabeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000174	0.00931	CbGpPWpGaD
Rabeprazole—Dyspepsia—Hydroxyurea—brain cancer	0.000174	0.0013	CcSEcCtD
Rabeprazole—Agitation—Temozolomide—brain cancer	0.000174	0.0013	CcSEcCtD
Rabeprazole—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000173	0.00925	CbGpPWpGaD
Rabeprazole—Angioedema—Temozolomide—brain cancer	0.000173	0.00129	CcSEcCtD
Rabeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000172	0.00922	CbGpPWpGaD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000172	0.00918	CbGpPWpGaD
Rabeprazole—Decreased appetite—Hydroxyurea—brain cancer	0.000172	0.00128	CcSEcCtD
Rabeprazole—Urinary tract disorder—Etoposide—brain cancer	0.000172	0.00128	CcSEcCtD
Rabeprazole—Malaise—Temozolomide—brain cancer	0.000171	0.00127	CcSEcCtD
Rabeprazole—Urethral disorder—Etoposide—brain cancer	0.00017	0.00127	CcSEcCtD
Rabeprazole—Vertigo—Temozolomide—brain cancer	0.00017	0.00127	CcSEcCtD
Rabeprazole—Convulsion—Carmustine—brain cancer	0.00017	0.00127	CcSEcCtD
Rabeprazole—Leukopenia—Temozolomide—brain cancer	0.000169	0.00126	CcSEcCtD
Rabeprazole—Hypertension—Carmustine—brain cancer	0.000169	0.00126	CcSEcCtD
Rabeprazole—Pain—Hydroxyurea—brain cancer	0.000169	0.00126	CcSEcCtD
Rabeprazole—Constipation—Hydroxyurea—brain cancer	0.000169	0.00126	CcSEcCtD
Rabeprazole—Dizziness—Procarbazine—brain cancer	0.000169	0.00126	CcSEcCtD
Rabeprazole—Palpitations—Temozolomide—brain cancer	0.000167	0.00125	CcSEcCtD
Rabeprazole—Chest pain—Carmustine—brain cancer	0.000167	0.00124	CcSEcCtD
Rabeprazole—Myalgia—Carmustine—brain cancer	0.000167	0.00124	CcSEcCtD
Rabeprazole—Anxiety—Carmustine—brain cancer	0.000166	0.00124	CcSEcCtD
Rabeprazole—Cough—Temozolomide—brain cancer	0.000165	0.00123	CcSEcCtD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000165	0.00881	CbGpPWpGaD
Rabeprazole—Erythema multiforme—Etoposide—brain cancer	0.000164	0.00123	CcSEcCtD
Rabeprazole—Convulsion—Temozolomide—brain cancer	0.000164	0.00122	CcSEcCtD
Rabeprazole—Hypertension—Temozolomide—brain cancer	0.000163	0.00122	CcSEcCtD
Rabeprazole—Feeling abnormal—Hydroxyurea—brain cancer	0.000163	0.00122	CcSEcCtD
Rabeprazole—Eye disorder—Etoposide—brain cancer	0.000162	0.00121	CcSEcCtD
Rabeprazole—Vomiting—Procarbazine—brain cancer	0.000162	0.00121	CcSEcCtD
Rabeprazole—Confusional state—Carmustine—brain cancer	0.000161	0.0012	CcSEcCtD
Rabeprazole—Myalgia—Temozolomide—brain cancer	0.000161	0.0012	CcSEcCtD
Rabeprazole—Arthralgia—Temozolomide—brain cancer	0.000161	0.0012	CcSEcCtD
Rabeprazole—Rash—Procarbazine—brain cancer	0.000161	0.0012	CcSEcCtD
Rabeprazole—Dermatitis—Procarbazine—brain cancer	0.000161	0.0012	CcSEcCtD
Rabeprazole—Anxiety—Temozolomide—brain cancer	0.00016	0.0012	CcSEcCtD
Rabeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00016	0.00856	CbGpPWpGaD
Rabeprazole—Headache—Procarbazine—brain cancer	0.00016	0.00119	CcSEcCtD
Rabeprazole—Oedema—Carmustine—brain cancer	0.00016	0.00119	CcSEcCtD
Rabeprazole—Discomfort—Temozolomide—brain cancer	0.000159	0.00119	CcSEcCtD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000158	0.00845	CbGpPWpGaD
Rabeprazole—Angiopathy—Etoposide—brain cancer	0.000158	0.00118	CcSEcCtD
Rabeprazole—Dry mouth—Temozolomide—brain cancer	0.000157	0.00118	CcSEcCtD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000157	0.00839	CbGpPWpGaD
Rabeprazole—Thrombocytopenia—Carmustine—brain cancer	0.000156	0.00117	CcSEcCtD
Rabeprazole—Body temperature increased—Hydroxyurea—brain cancer	0.000156	0.00117	CcSEcCtD
Rabeprazole—Chills—Etoposide—brain cancer	0.000156	0.00116	CcSEcCtD
Rabeprazole—Tachycardia—Carmustine—brain cancer	0.000156	0.00116	CcSEcCtD
Rabeprazole—Confusional state—Temozolomide—brain cancer	0.000156	0.00116	CcSEcCtD
Rabeprazole—Anaphylactic shock—Temozolomide—brain cancer	0.000154	0.00115	CcSEcCtD
Rabeprazole—Oedema—Temozolomide—brain cancer	0.000154	0.00115	CcSEcCtD
Rabeprazole—Alopecia—Etoposide—brain cancer	0.000154	0.00115	CcSEcCtD
Rabeprazole—Anorexia—Carmustine—brain cancer	0.000152	0.00114	CcSEcCtD
Rabeprazole—Nausea—Procarbazine—brain cancer	0.000152	0.00113	CcSEcCtD
Rabeprazole—Thrombocytopenia—Temozolomide—brain cancer	0.000151	0.00113	CcSEcCtD
Rabeprazole—Hypotension—Carmustine—brain cancer	0.000149	0.00111	CcSEcCtD
Rabeprazole—Hyperhidrosis—Temozolomide—brain cancer	0.000149	0.00111	CcSEcCtD
Rabeprazole—Dysgeusia—Etoposide—brain cancer	0.000148	0.00111	CcSEcCtD
Rabeprazole—Anorexia—Temozolomide—brain cancer	0.000147	0.0011	CcSEcCtD
Rabeprazole—Back pain—Etoposide—brain cancer	0.000146	0.00109	CcSEcCtD
Rabeprazole—Hypersensitivity—Hydroxyurea—brain cancer	0.000146	0.00109	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Carmustine—brain cancer	0.000145	0.00109	CcSEcCtD
Rabeprazole—Muscle spasms—Etoposide—brain cancer	0.000145	0.00109	CcSEcCtD
Rabeprazole—Insomnia—Carmustine—brain cancer	0.000144	0.00108	CcSEcCtD
Rabeprazole—Paraesthesia—Carmustine—brain cancer	0.000143	0.00107	CcSEcCtD
Rabeprazole—Dyspnoea—Carmustine—brain cancer	0.000142	0.00106	CcSEcCtD
Rabeprazole—Somnolence—Carmustine—brain cancer	0.000142	0.00106	CcSEcCtD
Rabeprazole—Asthenia—Hydroxyurea—brain cancer	0.000142	0.00106	CcSEcCtD
Rabeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000141	0.00754	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000141	0.00105	CcSEcCtD
Rabeprazole—Ill-defined disorder—Etoposide—brain cancer	0.00014	0.00105	CcSEcCtD
Rabeprazole—Anaemia—Etoposide—brain cancer	0.00014	0.00104	CcSEcCtD
Rabeprazole—Insomnia—Temozolomide—brain cancer	0.00014	0.00104	CcSEcCtD
Rabeprazole—Decreased appetite—Carmustine—brain cancer	0.000139	0.00104	CcSEcCtD
Rabeprazole—Paraesthesia—Temozolomide—brain cancer	0.000139	0.00103	CcSEcCtD
Rabeprazole—Dyspnoea—Temozolomide—brain cancer	0.000138	0.00103	CcSEcCtD
Rabeprazole—Somnolence—Temozolomide—brain cancer	0.000137	0.00102	CcSEcCtD
Rabeprazole—Pain—Carmustine—brain cancer	0.000137	0.00102	CcSEcCtD
Rabeprazole—Constipation—Carmustine—brain cancer	0.000137	0.00102	CcSEcCtD
Rabeprazole—Malaise—Etoposide—brain cancer	0.000136	0.00102	CcSEcCtD
Rabeprazole—Vertigo—Etoposide—brain cancer	0.000136	0.00101	CcSEcCtD
Rabeprazole—Dyspepsia—Temozolomide—brain cancer	0.000136	0.00101	CcSEcCtD
Rabeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000136	0.00725	CbGpPWpGaD
Rabeprazole—Leukopenia—Etoposide—brain cancer	0.000135	0.00101	CcSEcCtD
Rabeprazole—Diarrhoea—Hydroxyurea—brain cancer	0.000135	0.00101	CcSEcCtD
Rabeprazole—Decreased appetite—Temozolomide—brain cancer	0.000134	0.001	CcSEcCtD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000134	0.00716	CbGpPWpGaD
Rabeprazole—Loss of consciousness—Etoposide—brain cancer	0.000133	0.000993	CcSEcCtD
Rabeprazole—CYP1A1—Oxidative Stress—SOD2—brain cancer	0.000133	0.0071	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000132	0.00708	CbGpPWpGaD
Rabeprazole—Cough—Etoposide—brain cancer	0.000132	0.000986	CcSEcCtD
Rabeprazole—Pain—Temozolomide—brain cancer	0.000132	0.000985	CcSEcCtD
Rabeprazole—Constipation—Temozolomide—brain cancer	0.000132	0.000985	CcSEcCtD
Rabeprazole—Feeling abnormal—Carmustine—brain cancer	0.000132	0.000982	CcSEcCtD
Rabeprazole—Convulsion—Etoposide—brain cancer	0.000131	0.000979	CcSEcCtD
Rabeprazole—Hypertension—Etoposide—brain cancer	0.000131	0.000975	CcSEcCtD
Rabeprazole—Dizziness—Hydroxyurea—brain cancer	0.000131	0.000975	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Carmustine—brain cancer	0.000131	0.000975	CcSEcCtD
Rabeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00013	0.00694	CbGpPWpGaD
Rabeprazole—Chest pain—Etoposide—brain cancer	0.000129	0.000962	CcSEcCtD
Rabeprazole—Discomfort—Etoposide—brain cancer	0.000127	0.00095	CcSEcCtD
Rabeprazole—Feeling abnormal—Temozolomide—brain cancer	0.000127	0.000949	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000126	0.00675	CbGpPWpGaD
Rabeprazole—Abdominal pain—Carmustine—brain cancer	0.000126	0.000942	CcSEcCtD
Rabeprazole—Body temperature increased—Carmustine—brain cancer	0.000126	0.000942	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Temozolomide—brain cancer	0.000126	0.000942	CcSEcCtD
Rabeprazole—Vomiting—Hydroxyurea—brain cancer	0.000126	0.000938	CcSEcCtD
Rabeprazole—Rash—Hydroxyurea—brain cancer	0.000125	0.00093	CcSEcCtD
Rabeprazole—Confusional state—Etoposide—brain cancer	0.000125	0.000929	CcSEcCtD
Rabeprazole—Dermatitis—Hydroxyurea—brain cancer	0.000124	0.000929	CcSEcCtD
Rabeprazole—Headache—Hydroxyurea—brain cancer	0.000124	0.000924	CcSEcCtD
Rabeprazole—Anaphylactic shock—Etoposide—brain cancer	0.000123	0.000922	CcSEcCtD
Rabeprazole—Urticaria—Temozolomide—brain cancer	0.000123	0.000915	CcSEcCtD
Rabeprazole—Abdominal pain—Temozolomide—brain cancer	0.000122	0.000911	CcSEcCtD
Rabeprazole—Body temperature increased—Temozolomide—brain cancer	0.000122	0.000911	CcSEcCtD
Rabeprazole—Thrombocytopenia—Etoposide—brain cancer	0.000121	0.000903	CcSEcCtD
Rabeprazole—Tachycardia—Etoposide—brain cancer	0.000121	0.0009	CcSEcCtD
Rabeprazole—Hyperhidrosis—Etoposide—brain cancer	0.000119	0.000891	CcSEcCtD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000118	0.00631	CbGpPWpGaD
Rabeprazole—Anorexia—Etoposide—brain cancer	0.000118	0.000879	CcSEcCtD
Rabeprazole—Hypersensitivity—Carmustine—brain cancer	0.000118	0.000878	CcSEcCtD
Rabeprazole—Nausea—Hydroxyurea—brain cancer	0.000117	0.000876	CcSEcCtD
Rabeprazole—Hypotension—Etoposide—brain cancer	0.000115	0.000861	CcSEcCtD
Rabeprazole—Asthenia—Carmustine—brain cancer	0.000115	0.000855	CcSEcCtD
Rabeprazole—Hypersensitivity—Temozolomide—brain cancer	0.000114	0.000849	CcSEcCtD
Rabeprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—brain cancer	0.000113	0.00607	CbGpPWpGaD
Rabeprazole—Paraesthesia—Etoposide—brain cancer	0.000111	0.000828	CcSEcCtD
Rabeprazole—Asthenia—Temozolomide—brain cancer	0.000111	0.000827	CcSEcCtD
Rabeprazole—Dyspnoea—Etoposide—brain cancer	0.00011	0.000822	CcSEcCtD
Rabeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00011	0.00588	CbGpPWpGaD
Rabeprazole—Somnolence—Etoposide—brain cancer	0.00011	0.000819	CcSEcCtD
Rabeprazole—Diarrhoea—Carmustine—brain cancer	0.000109	0.000816	CcSEcCtD
Rabeprazole—Pruritus—Temozolomide—brain cancer	0.000109	0.000815	CcSEcCtD
Rabeprazole—Decreased appetite—Etoposide—brain cancer	0.000107	0.000801	CcSEcCtD
Rabeprazole—Dizziness—Carmustine—brain cancer	0.000106	0.000788	CcSEcCtD
Rabeprazole—Constipation—Etoposide—brain cancer	0.000106	0.000788	CcSEcCtD
Rabeprazole—Pain—Etoposide—brain cancer	0.000106	0.000788	CcSEcCtD
Rabeprazole—Diarrhoea—Temozolomide—brain cancer	0.000106	0.000788	CcSEcCtD
Rabeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000105	0.0056	CbGpPWpGaD
Rabeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000103	0.00552	CbGpPWpGaD
Rabeprazole—Dizziness—Temozolomide—brain cancer	0.000102	0.000762	CcSEcCtD
Rabeprazole—Feeling abnormal—Etoposide—brain cancer	0.000102	0.00076	CcSEcCtD
Rabeprazole—Vomiting—Carmustine—brain cancer	0.000102	0.000758	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Etoposide—brain cancer	0.000101	0.000754	CcSEcCtD
Rabeprazole—Rash—Carmustine—brain cancer	0.000101	0.000752	CcSEcCtD
Rabeprazole—Dermatitis—Carmustine—brain cancer	0.000101	0.000751	CcSEcCtD
Rabeprazole—Headache—Carmustine—brain cancer	0.0001	0.000747	CcSEcCtD
Rabeprazole—Vomiting—Temozolomide—brain cancer	9.81e-05	0.000732	CcSEcCtD
Rabeprazole—Urticaria—Etoposide—brain cancer	9.81e-05	0.000732	CcSEcCtD
Rabeprazole—Abdominal pain—Etoposide—brain cancer	9.76e-05	0.000729	CcSEcCtD
Rabeprazole—Body temperature increased—Etoposide—brain cancer	9.76e-05	0.000729	CcSEcCtD
Rabeprazole—Rash—Temozolomide—brain cancer	9.73e-05	0.000726	CcSEcCtD
Rabeprazole—Dermatitis—Temozolomide—brain cancer	9.72e-05	0.000726	CcSEcCtD
Rabeprazole—Headache—Temozolomide—brain cancer	9.67e-05	0.000722	CcSEcCtD
Rabeprazole—Nausea—Carmustine—brain cancer	9.49e-05	0.000708	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	9.45e-05	0.00505	CbGpPWpGaD
Rabeprazole—Nausea—Temozolomide—brain cancer	9.17e-05	0.000684	CcSEcCtD
Rabeprazole—CYP1A1—Biological oxidations—CYP2C9—brain cancer	9.16e-05	0.0049	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Etoposide—brain cancer	9.1e-05	0.000679	CcSEcCtD
Rabeprazole—CYP1A1—Metapathway biotransformation—CYP2C9—brain cancer	9.03e-05	0.00483	CbGpPWpGaD
Rabeprazole—CYP3A4—Irinotecan Pathway—APC—brain cancer	8.89e-05	0.00475	CbGpPWpGaD
Rabeprazole—Asthenia—Etoposide—brain cancer	8.86e-05	0.000661	CcSEcCtD
Rabeprazole—Pruritus—Etoposide—brain cancer	8.74e-05	0.000652	CcSEcCtD
Rabeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	8.48e-05	0.00454	CbGpPWpGaD
Rabeprazole—Diarrhoea—Etoposide—brain cancer	8.45e-05	0.000631	CcSEcCtD
Rabeprazole—Dizziness—Etoposide—brain cancer	8.17e-05	0.00061	CcSEcCtD
Rabeprazole—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	7.88e-05	0.00422	CbGpPWpGaD
Rabeprazole—Vomiting—Etoposide—brain cancer	7.85e-05	0.000586	CcSEcCtD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—brain cancer	7.85e-05	0.0042	CbGpPWpGaD
Rabeprazole—Rash—Etoposide—brain cancer	7.79e-05	0.000581	CcSEcCtD
Rabeprazole—Dermatitis—Etoposide—brain cancer	7.78e-05	0.000581	CcSEcCtD
Rabeprazole—Headache—Etoposide—brain cancer	7.74e-05	0.000577	CcSEcCtD
Rabeprazole—CYP2C19—Biological oxidations—CYP2C9—brain cancer	7.49e-05	0.00401	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	7.39e-05	0.00395	CbGpPWpGaD
Rabeprazole—Nausea—Etoposide—brain cancer	7.33e-05	0.000548	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	7.24e-05	0.00387	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—CYP2C9—brain cancer	6.89e-05	0.00369	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	6.8e-05	0.00364	CbGpPWpGaD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TP53—brain cancer	6.07e-05	0.00325	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	6.02e-05	0.00322	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—S100A10—brain cancer	5.96e-05	0.00319	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—CYP2C9—brain cancer	5.84e-05	0.00312	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	5.76e-05	0.00308	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—RELA—brain cancer	5.45e-05	0.00291	CbGpPWpGaD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	5.39e-05	0.00288	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	4.91e-05	0.00262	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—brain cancer	4.62e-05	0.00247	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—CYP2C9—brain cancer	4.51e-05	0.00241	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	4.44e-05	0.00238	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	4.17e-05	0.00223	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.84e-05	0.00205	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	3.75e-05	0.00201	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.75e-05	0.00201	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.52e-05	0.00188	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	3.47e-05	0.00186	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	3.13e-05	0.00167	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.88e-05	0.00154	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—TRPC6—brain cancer	2.75e-05	0.00147	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	2.66e-05	0.00142	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.57e-05	0.00137	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	2.45e-05	0.00131	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	2.39e-05	0.00128	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	2.39e-05	0.00128	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP2C9—brain cancer	2.31e-05	0.00124	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.24e-05	0.0012	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.1e-05	0.00113	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—BSG—brain cancer	1.97e-05	0.00105	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.92e-05	0.00103	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—IDH1—brain cancer	1.69e-05	0.000905	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.64e-05	0.000877	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYP2C9—brain cancer	1.57e-05	0.000837	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—ENO2—brain cancer	1.34e-05	0.000715	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—BSG—brain cancer	1.33e-05	0.000712	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP2C9—brain cancer	1.28e-05	0.000685	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP2C9—brain cancer	1.18e-05	0.00063	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—IDH1—brain cancer	1.15e-05	0.000612	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—BSG—brain cancer	1.09e-05	0.000583	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—BSG—brain cancer	1e-05	0.000536	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP2C9—brain cancer	9.99e-06	0.000534	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—BSG—brain cancer	9.94e-06	0.000531	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—IDH1—brain cancer	9.37e-06	0.000501	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.32e-06	0.000499	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—ENO2—brain cancer	9.05e-06	0.000484	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—IDH1—brain cancer	8.62e-06	0.000461	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—IDH1—brain cancer	8.54e-06	0.000457	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—BSG—brain cancer	8.49e-06	0.000454	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYP2C9—brain cancer	7.71e-06	0.000412	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.63e-06	0.000408	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—ENO2—brain cancer	7.41e-06	0.000396	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—IDH1—brain cancer	7.3e-06	0.00039	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.96e-06	0.000372	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—ENO2—brain cancer	6.81e-06	0.000364	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—ENO2—brain cancer	6.75e-06	0.000361	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—BSG—brain cancer	6.55e-06	0.00035	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CG—brain cancer	6.13e-06	0.000328	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.94e-06	0.000318	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—ENO2—brain cancer	5.77e-06	0.000309	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—IDH1—brain cancer	5.63e-06	0.000301	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—ENO2—brain cancer	4.45e-06	0.000238	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CG—brain cancer	4.15e-06	0.000222	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CG—brain cancer	3.4e-06	0.000182	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CG—brain cancer	3.13e-06	0.000167	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CG—brain cancer	3.1e-06	0.000166	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CG—brain cancer	2.65e-06	0.000142	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CG—brain cancer	2.04e-06	0.000109	CbGpPWpGaD
